TOURMALINE-MM2: Oral Ixazomib-Rd vs Placebo-Rd for ASCT-Ineligible Patients With Newly Diagnosed MM

December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting
The addition of ixazomib to Rd was reasonably well tolerated and conferred a clinically meaningful, but not statistically significant 13.5-month improvement in PFS compared with the control arm.
Format: Microsoft PowerPoint (.ppt)
File Size: 391 KB
Released: December 9, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
AstraZeneca
Bristol-Myers Squibb
Epizyme Inc.
GlaxoSmithKline
Incyte Corporation
Janssen Biotech, Inc.
Karyopharm Therapeutics Inc.
Novartis
PharmaEssentia Corp.
Seattle Genetics
Takeda Oncology

Related Content

Experts highlight key studies presented at the 2022 EHA annual meeting in this commentary from Clinical Care Options (CCO)

Stéphane de Botton, MD Jesús F. San-Miguel, MD, PhD Alessandra Tedeschi, MD Released: June 20, 2022

Slides from Clinical Care Options (CCO) with key findings on BTK inhibitors in CLL and MCL from the 2022 ASCO, EHA, Pan Pacific, ESMO, and SOHO meetings

Released: June 17, 2022

Phase II trial shows high response rates and high 3-year EFS and OS rates with crenolanib plus 7+3 chemotherapy in newly diagnosed FLT3-mutated AML, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 17, 2022

Results from retrospective Pre-MEASURE study evaluating the prognostic value of NGS-MRD testing in patients with AML in first remission prior to allogeneic HCT, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 17, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings